Abstract Treatment of human immunodeficiency virus(HIV) in cancer patients improves outcomes and reduces transmission of this oncogenic virus. HIV testing rates of cancer patients are similar to the

Immunotherapy with ’checkpoint-inhibitors‘ has significantly improved outcomes for patients with a range of malignancies. However, significant immune-mediated toxicities of these therapies are